Cross-Reactivity of Rabbit Anti-Bovine Thrombin IgGs With Human α-Thrombin and a Recombinant Version of Human Thrombin (Recothrom)

Abstract

It has been reported that patients exposed to topical bovine thrombin preparations may develop antibodies against bovine thrombin, factr V or various other proteins found in these preparations. Such antibodies can cross-react with human endogenous coagulation proteins and may lead to alterations in the coagulation laboratory parameters, hypersensitivity reactions, and severe bleeding or thrombosis. The underlying mechanisms for the coagulopathy are not fully understood yet. To better understand the cross-reactivity of anti-bovine thrombin antibodies with human corresponding coagulation proteins, bovine crude thrombin, and its purified versions, thrombin 4A (the old version of Thrombin-JMI before year 2008) and thrombin 4B (the current version of Thrombin-JMI on market), were used to generate relevant anti-bovine thrombin immunoglobulin G (IgGs) in rabbits. Using Western blotting, the cross-reactivity of each IgG with human α-thrombin and a recombinant version of human thrombin (Recothrom) was investigated. The results indicated that no cross-reactivity with either human α-thrombin or Recothrom was observed with both anti-bovine crude thrombin IgGs and thrombin 4B IgGs. However, anti-bovine thrombin 4A IgGs showed apparent cross-reactivity with human α-thrombin and Recothrom in a protein amount-dependent manner. Furthermore, the results revealed that the cross-reactivity of anti-bovine thrombin 4A IgGs with human α-thrombin and Recothrom was immunization time-dependent. The minimum concentration of 4A IgG required to exhibit cross-reactivity with human α-thrombin and Recothrom varied considerably among individual rabbits. These results indicate that rabbit anti-bovine thrombin IgGs can cross-react with human α-thrombin and Recothrom, suggesting that human antibodies against bovine thrombin may also cross-react with human recombinant thrombin. Thus, the patients who were previously exposed to bovine thrombin may also develop antibodies which can cross-react with human recombinant thrombin.

Keywords

bovine thrombin human thrombin Western blot immunoglobulin G topical hemostatic agents

References

Schoenecker JG , Hauck RK , Mercer MC , Parker W. , Lawson JH Exposure to topical bovine thrombin during surgery elicits a response against the xenogenic carbohydrate galactose alpha1-3galactose . J Clin Immunol. 2000;20(6):434-444.

Lawson JH The clinical use and immunologic impact of thrombin in surgery. Semin Thromb hemost. 2006;32(S1):98-110.

Terrab A. , Pawlak D. , Spaay P. , Hoppensteadt D. , Fareed J. Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost . 2008;14(2):135-140.

Nelson PA , Powers JN , Estridge TD , et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res. 2001;58(6):710-719.

Rapaport SI , Zivelin A. , Minow RA , Hunter CS , Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol . 1992;97(1):84-91.

Cmolik BL , Spero JA , Magovern GJ , Clark RE Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac cardiovasc Surg. 1993;105(2):222-228.

Chouhan VD , De la cadena RA , Nagaswami C. , Weisel JW , Kajani M. , Rao AK Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V after exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost . 1997;77(2):343-349.

Winterbottom N. , Kuo JM , Nguyen K. , et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients . J Applied Res. 2002;2:1-11.

Ortel TL , Charles LA , Keller FG , et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994;45(2):128-135.

10.

Zehnder JL , Leung LLK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990;76(10):2011-2016.

11.

Lawson JH , Lynn KA , Vanmatre RM , et al. Antihuman factor V antibodies after use of relative pure bovine thrombin. Ann Thorac Surg. 2005;79(3):1037-1038.

12.

Ortel TL , Mercer MC , Thames EH , Moore KD , Lawson JH Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233(1):88-96.

13.

Sands JJ , Nudo SA , Ashford RG , Moore KD , Ortel TL Antibodies to topical bovine thrombin correlate with access thrombosis . Am J kidney Dis. 2000;35(5):796-801.

14.

Sarfati MR , Dilorenzo DJ , Kraiss LW , Galt SW Severe coagulopathy following intraoperative use of topical thrombin . Ann Vasc Surg. 2004;18(3):349-351.

15.

Savage WJ , Kickler TS , Takemoto CM Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer. 2007 ;49(7):1025-1029.

16.

Streiff MB , Ness PM Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002;42(1):18-26.

17.

Heffernan JK , Ponce RA , Zuckerman LA , et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol . 2007 ;47(1):48-58.

18.

Chapman WC , Lockstadt H. , Singla N. , Kafie FE , Lawson JH Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications . J Thromb Haemost. 2006;4(9): 2083-2085.

19.

Chapman WC , Singla N. , Genyk Y. , et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007 ;205(2):256-265.

20.

Weaver F. , Lew W. , Granke K. , et al; Study Investigators. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg. 2008; 47(6):1266-1273.

21.

Greenhalgh DG , Gamelli RL , Collins J. , et al. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res. 2009;30(3):371-379.

22.

Singla NK , Ballard JL , Moneta G. , Randleman CD Jr , Renkens KL , Alexander WA A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg. 2009;209(1):68-74.

23.

Sandermann H. Jr , Stromiger JL Purification and properties of C 55-isoprenoid alcohol phosphokinase from staphylococcus aureus. J. Biol. Chem. 1972;247(16): 5123-5131.

24.

Zhu H. , Hoppensteadt D. , Cunanan J. , et al. Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostaic application. Clin Appl Thromb Hemost . 2008;15(1):32-40.

25.

Zhu H. , Hoppensteadt D. , Adiguzel C. , Bick RL , Fareed J. Comparison of immunogenic potentials of bovine thrombin preparations . Clin Appl Thromb Hemost. 2008;15(1):41-49.

26.

RecothromTM [Package insert]. Seattle, WA : Zymogenetics; 2008.